Quantcast

Latest ImmunoCellular Therapeutics Ltd. Stories

2014-09-26 08:24:57

LOS ANGELES, Sept. 26, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, will present a corporate overview and business update at the Livingston Securities 7(th) Annual Life Sciences Stakeholders Summit at 1:55 pm ET on Wednesday, October 1, 2014, at the Cira Center in Philadelphia, PA. http://photos.prnewswire.com/prnvar/20140109/AQ43875LOGO To access the live audio webcast of...

2014-09-24 08:27:24

Ex-Vivo Manipulation of Autologous Hematopoietic Stem Cells Complements Dendritic Cell-based Vaccine Platform; Potential to Develop Single-Agent and Combination Immunotherapeutics LOS ANGELES, Sept. 24, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today that it has established a licensing agreement with the California Institute of Technology (Caltech) for exclusive rights to novel technology for the development of certain...

2014-09-17 08:28:28

ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track LOS ANGELES, Sept. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) provides a corporate update on its plans to advance ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM), and on its portfolio of dendritic cell-based vaccines: ICT-121 for patients...

2014-08-07 16:28:52

Conference Call Today at 5:00 pm ET LOS ANGELES, Aug. 7, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the quarter ended June 30, 2014. http://photos.prnewswire.com/prnvar/20140109/AQ43875LOGO For the quarter ended June 30, 2014, the Company incurred a net loss of $2.2 million, or $0.04 per basic and diluted share, compared to a net loss of $150,000, or $0.00 per basic and diluted share for the...

2014-07-29 16:26:56

LOS ANGELES, July 29, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report second quarter 2014 financial results on Thursday, August 7, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO. LIVE CALL: (877) 853-5636...

2014-06-01 08:20:27

Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients LOS ANGELES, June 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical...

2014-05-20 12:21:42

Editor Note: For more information about this release, please scroll to bottom LONDON, May 20, 2014 /PRNewswire/ -- The US markets saw a positive sentiment on Monday, May 19, 2014, with the NASDAQ Composite closing at 4,125.82, up 0.86%, the Dow Jones Industrial Average ending the session 0.12% higher at 16,511.86, and the S&P 500 edging 0.38% higher to finish the trading session at 1,885.08. During the session gains in the Information Technology, Health Care, and Financials...

2014-05-08 16:26:51

Conference Call Today at 5:00 pm ET LOS ANGELES, May 8, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the quarter ended March 31, 2014. http://photos.prnewswire.com/prnvar/20140109/AQ43875LOGO For the quarter ended March 31, 2014, the Company incurred a net loss of $3.2 million, or $0.05 per basic and diluted share, compared to a net loss of $5.0 million, or $0.10 per basic and diluted share for...

2014-05-01 08:33:37

LOS ANGELES, May 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report first quarter 2014 financial results on Thursday, May 8, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO. http://photos.prnewswire.com/prnvar/20140109/AQ43875LOGO LIVE...

2014-04-21 16:25:24

LOS ANGELES, April 21, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the abstract describing the Company's phase II trial of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed glioblastoma (GBM) has been accepted for an oral presentation at the 2014 American Society for Clinical Oncology (ASCO) annual meeting, to be held in Chicago May 30-June 3, 2014....


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related